A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
ILLUSTRATE
Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.
1 other identifier
interventional
1,100
6 countries
146
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary heart disease
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Oct 2003
Typical duration for phase_3
146 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2003
CompletedFirst Submitted
Initial submission to the registry
August 22, 2005
CompletedFirst Posted
Study publicly available on registry
August 24, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2006
CompletedDecember 10, 2007
April 1, 2007
August 22, 2005
December 6, 2007
Conditions
Outcome Measures
Primary Outcomes (1)
Change coronary artery atheroma volume as measured by intravascular ultrasound.
Secondary Outcomes (1)
Changes in levels of lipids and other biomarkers.
Interventions
Eligibility Criteria
You may qualify if:
- angiographic evidence of coronary atherosclerosis
You may not qualify if:
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid.
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (146)
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Mobile, Alabama, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
Los Altos, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Mountain View, California, United States
Pfizer Investigational Site
Sacramento, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
Santa Rosa, California, United States
Pfizer Investigational Site
Stockton, California, United States
Pfizer Investigational Site
Boulder, Colorado, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Brandford, Connecticut, United States
Pfizer Investigational Site
Farmington, Connecticut, United States
Pfizer Investigational Site
Guilford, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
Atlantis, Florida, United States
Pfizer Investigational Site
Clearwater, Florida, United States
Pfizer Investigational Site
Dunedin, Florida, United States
Pfizer Investigational Site
Fort Lauderdale, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Largo, Florida, United States
Pfizer Investigational Site
Melbourne, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
Pensacola, Florida, United States
Pfizer Investigational Site
Safety Harbor, Florida, United States
Pfizer Investigational Site
Sarasota, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Blue Island, Illinois, United States
Pfizer Investigational Site
Merrionette Park, Illinois, United States
Pfizer Investigational Site
Rockford, Illinois, United States
Pfizer Investigational Site
Elkhart, Indiana, United States
Pfizer Investigational Site
Goshen, Indiana, United States
Pfizer Investigational Site
Hobart, Indiana, United States
Pfizer Investigational Site
Merrillville, Indiana, United States
Pfizer Investigational Site
Davenport, Iowa, United States
Pfizer Investigational Site
Des Moines, Iowa, United States
Pfizer Investigational Site
West Des Moines, Iowa, United States
Pfizer Investigational Site
Shawnee Mission, Kansas, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
Bogalusa, Louisiana, United States
Pfizer Investigational Site
Covington, Louisiana, United States
Pfizer Investigational Site
New Orleans, Louisiana, United States
Pfizer Investigational Site
Auburn, Maine, United States
Pfizer Investigational Site
Lewiston, Maine, United States
Pfizer Investigational Site
Portland, Maine, United States
Pfizer Investigational Site
Scarborough, Maine, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Columbia, Maryland, United States
Pfizer Investigational Site
Salisbury, Maryland, United States
Pfizer Investigational Site
Takoma Park, Maryland, United States
Pfizer Investigational Site
Ann Arbor, Michigan, United States
Pfizer Investigational Site
Flint, Michigan, United States
Pfizer Investigational Site
Kalamazoo, Michigan, United States
Pfizer Investigational Site
Lapeer, Michigan, United States
Pfizer Investigational Site
Petoskey, Michigan, United States
Pfizer Investigational Site
Royal Oak, Michigan, United States
Pfizer Investigational Site
Saginaw, Michigan, United States
Pfizer Investigational Site
Ypsilanti, Michigan, United States
Pfizer Investigational Site
Duluth, Minnesota, United States
Pfizer Investigational Site
Maplewood, Minnesota, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Saint Cloud, Minnesota, United States
Pfizer Investigational Site
Saint Paul, Minnesota, United States
Pfizer Investigational Site
Southaven, Mississippi, United States
Pfizer Investigational Site
Kansas City, Missouri, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Ridgewood, New Jersey, United States
Pfizer Investigational Site
Albuquerque, New Mexico, United States
Pfizer Investigational Site
Carlsbad, New Mexico, United States
Pfizer Investigational Site
Albany, New York, United States
Pfizer Investigational Site
Bay Shore, New York, United States
Pfizer Investigational Site
Buffalo, New York, United States
Pfizer Investigational Site
Flushing, New York, United States
Pfizer Investigational Site
Johnson City, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Oneonta, New York, United States
Pfizer Investigational Site
Poughkeepsie, New York, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Troy, New York, United States
Pfizer Investigational Site
Williamsville, New York, United States
Pfizer Investigational Site
Eden, North Carolina, United States
Pfizer Investigational Site
Greensboro, North Carolina, United States
Pfizer Investigational Site
Greenville, North Carolina, United States
Pfizer Investigational Site
Raleigh, North Carolina, United States
Pfizer Investigational Site
Reidsville, North Carolina, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, United States
Pfizer Investigational Site
Bellevue, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Clyde, Ohio, United States
Pfizer Investigational Site
Defiance, Ohio, United States
Pfizer Investigational Site
Fostoria, Ohio, United States
Pfizer Investigational Site
Middleburg Heights, Ohio, United States
Pfizer Investigational Site
Orange, Ohio, United States
Pfizer Investigational Site
Toledo, Ohio, United States
Pfizer Investigational Site
Wauseon, Ohio, United States
Pfizer Investigational Site
Westlake, Ohio, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Tulsa, Oklahoma, United States
Pfizer Investigational Site
Eugene, Oregon, United States
Pfizer Investigational Site
Florence, Oregon, United States
Pfizer Investigational Site
Hillsboro, Oregon, United States
Pfizer Investigational Site
Doylestown, Pennsylvania, United States
Pfizer Investigational Site
Harrisburg, Pennsylvania, United States
Pfizer Investigational Site
Hershey, Pennsylvania, United States
Pfizer Investigational Site
Lancaster, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States
Pfizer Investigational Site
Wormleysburg, Pennsylvania, United States
Pfizer Investigational Site
Greenville, South Carolina, United States
Pfizer Investigational Site
Chattanooga, Tennessee, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Oak Ridge, Tennessee, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Annandale, Virginia, United States
Pfizer Investigational Site
Charlottesville, Virginia, United States
Pfizer Investigational Site
Falls Church, Virginia, United States
Pfizer Investigational Site
Norfolk, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Bellevue, Washington, United States
Pfizer Investigational Site
Seattle, Washington, United States
Pfizer Investigational Site
Huntington, West Virginia, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Aalst, Belgium
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Genk, Belgium
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Torono, Ontario, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Nijmegen, Netherlands
Pfizer Investigational Site
Rotterdam, Netherlands
Pfizer Investigational Site
Katowice, Poland
Pfizer Investigational Site
Krakow, Poland
Pfizer Investigational Site
Warsaw, Poland
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
L´Hospitalet Del Llobregat, Barcelona, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Vigo, Pontevedra, Spain
Pfizer Investigational Site
Oviedo, Principality of Asturias, Spain
Related Publications (2)
Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008 Dec 9;118(24):2506-14. doi: 10.1161/CIRCULATIONAHA.108.790733. Epub 2008 Nov 24.
PMID: 19029466DERIVEDNissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007 Mar 29;356(13):1304-16. doi: 10.1056/NEJMoa070635. Epub 2007 Mar 26.
PMID: 17387129DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 22, 2005
First Posted
August 24, 2005
Study Start
October 1, 2003
Study Completion
September 1, 2006
Last Updated
December 10, 2007
Record last verified: 2007-04